This month, AbbVie gave iStar Medical an upfront cash payment to continue the development of its glaucoma devices, with the deal also granting AbbVie the option to purchase iSTAR outright for nearly half a billion dollars. (Also see "Minute Insight: AbbVie Bets Big On Glaucoma Market With iSTAR Purchase Deal" - Medtech Insight, 20 July, 2022.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?